Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors
- 1 February 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (5) , 760-771
- https://doi.org/10.1021/jm9707378
Abstract
A series of {4-[2-(4-arylpiperazin-1-yl)alkyl]cyclohexyl}pyrimidin-2-ylamines was prepared and found to have receptor binding affinity for D2 and D3 dopamine (DA) receptors and serotonin 5-HT1A receptors. The structural contributions to D2/D3 and 5-HT1A receptor binding of the aminopyrimidine, cycloalkyl, and phenylpiperazine portions of the molecule were examined. From these studies compounds 14, 39, 42, 43, having potent affinity for both DA D2 and 5-HT1A receptors, were evaluated for intrinsic activity at these receptors, in vitro and in vivo. Compound 14 (PD 158771) had a profile indicative of partial agonist activity at both D2 and 5-HT1A receptors causing partially decreased synthesis of the neurotransmitters DA and 5-HT and their metabolites. This compound has a profile in behavioral tests that is predictive of antipsychotic activity, suggesting that mixed partial agonists such as 14 may have utility as antipsychotic agents with increased efficacy and decreased side effects.Keywords
This publication has 11 references indexed in Scilit:
- Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligandsBioorganic & Medicinal Chemistry Letters, 1997
- 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as Dopamine D2 Partial Agonists and Autoreceptor AgonistsJournal of Medicinal Chemistry, 1997
- 3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic AgentsJournal of Medicinal Chemistry, 1996
- 5-HT1A receptor agonists: recent developments and controversial issuesPsychopharmacology, 1995
- Olanzapine < Prop INN; USAN >Drugs of the Future, 1994
- Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primatesPsychopharmacology, 1993
- Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptidePsychopharmacology, 1989
- Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activityEuropean Journal of Pharmacology, 1988
- Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brainBrain Research, 1985
- Dopamine receptor agonists: Intrinsic activity vs. state of receptorJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1983